October 18, 2024
The American Heart Association (AHA) has issued a new scientific statement on the link between heart failure (HF), atrial fibrillation (AF), and coronary heart disease (CHD) […]
October 18, 2024
TOPLINE: Galcanezumab was associated with significantly less dizziness in patients with vestibular migraine (VM) compared with placebo, suggests new results from the first randomized clinical trial […]
October 17, 2024
The US Food and Drug Administration (FDA) has approved Avadel Pharmaceuticals’ supplemental new drug application for extended-release sodium oxybate (Lumryz) for treatment of cataplexy or excessive […]
October 16, 2024
SAVANNAH, GEORGIA – The investigational monoclonal antibody nipocalimab (Johnson & Johnson) is associated with significant improvement in patients with generalized myasthenia gravis (gMG) over a 24-week […]
October 14, 2024
Sleep patterns, physical activity, mood, and heart rate can affect brain connectivity in the short and longer term, results of a unique precision brain mapping study […]
October 11, 2024
Older adults at risk for dementia can be identified using mobile data obtained during a wayfinding task, a novel real-world study suggested. During a smartphone-assisted scavenger […]
October 11, 2024
PHILADELPHIA — Early adjuvant use of opicapone (Ongentys) may reduce the risk for complications in patients with early Parkinson’s disease (PD) and no motor complications. The […]
October 11, 2024
PHILADELPHIA — The experimental vaccine UB-312 shows early promise in Parkinson’s disease (PD) and multiple system atrophy (MSA), results of a phase 1b study suggest. “UB-312 […]
October 10, 2024
A first stroke in older adults is associated with substantial immediate and accelerated long-term cognitive decline, suggested a new study that underscores the need for continuous […]